Ion channels in the immune system as targets for immu

Current Opinion in Biotechnology
8, 749-756
DOI: 10.1016/s0958-1669(97)80130-9

Citation Report

#	Article	IF	Citations
1	Potassium ion channels and human disease: phenotypes to drug targets?. Current Opinion in Biotechnology, 1998, 9, 565-572.	3.3	36
2	Alkoxypsoralens, Novel Nonpeptide Blockers ofShaker-Type K+Channels:Â Synthesis and Photoreactivity. Journal of Medicinal Chemistry, 1998, 41, 4542-4549.	2.9	51
3	A Nongenomic Mechanism for Progesterone-mediated Immunosuppression: Inhibition of K+ Channels, Ca2+ Signaling, and Gene Expression in T Lymphocytes. Journal of Experimental Medicine, 1998, 188, 1593-1602.	4.2	153
4	ShK-Dap22, a Potent Kv1.3-specific Immunosuppressive Polypeptide. Journal of Biological Chemistry, 1998, 273, 32697-32707.	1.6	222
5	Structural Conservation of the Pores of Calcium-activated and Voltage-gated Potassium Channels Determined by a Sea Anemone Toxin. Journal of Biological Chemistry, 1999, 274, 21885-21892.	1.6	119
6	UK-78,282, a novel piperidine compound that potently blocks the Kv1.3 voltage-gated potassium channel and inhibits human T cell activation. British Journal of Pharmacology, 1999, 126, 1707-1716.	2.7	57
7	Correolide and Derivatives Are Novel Immunosuppressants Blocking the Lymphocyte Kv1.3 Potassium Channels. Cellular Immunology, 1999, 197, 99-107.	1.4	86
8	Single-Channel Recording of a Store-Operated Ca2+ Channel in Jurkat T Lymphocytes. Science, 1999, 283, 836-839.	6.0	136
9	K+ channel-blocking alkoxypsoralens inhibit the immune response of encephalitogenic T line cells and lymphocytes from Lewis rats challenged for experimental autoimmune encephalomyelitis. Immunopharmacology, 2000, 48, 51-63.	2.0	21
10	Block of the lymphocyte K+ channel m Kv1.3 by the phenylalkylamine verapamil: Kinetic aspects of block and disruption of accumulation of block by a single point mutation. British Journal of Pharmacology, 2000, 131, 1275-1284.	2.7	21
11	Bioenergetics of Human Peripheral Blood Mononuclear Cell Metabolism in Quiescent, Activated, and Glucocorticoid-Treated States. Bioscience Reports, 2000, 20, 289-302.	1.1	70
12	Cell volume regulation in immune cell apoptosis. Cell and Tissue Research, 2000, 301, 33-42.	1.5	64
13	Design of a potent and selective inhibitor of the intermediate-conductance Ca2+-activated K+ channel, IKCa1: A potential immunosuppressant. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 8151-8156.	3.3	553
14	Up-regulation of the IKCa1 Potassium Channel during T-cell Activation. Journal of Biological Chemistry, 2000, 275, 37137-37149.	1.6	357
15	Structure-guided Transformation of Charybdotoxin Yields an Analog That Selectively Targets Ca2+-activated over Voltage-gated K+ Channels. Journal of Biological Chemistry, 2000, 275, 1201-1208.	1.6	94
16	Protein Kinase C (PKC) Inhibits Fas Receptor-induced Apoptosis through Modulation of the Loss of K+ and Cell Shrinkage. Journal of Biological Chemistry, 2000, 275, 19609-19619.	1.6	116
17	Generating a High Affinity Scorpion Toxin Receptor in KcsA-Kv1.3 Chimeric Potassium Channels. Journal of Biological Chemistry, 2000, 275, 16918-16924.	1.6	67
18	Recent Developments in the Biology and Medicinal Chemistry of Potassium Channel Modulators:Â Update from a Decade of Progress. Journal of Medicinal Chemistry, 2001, 44, 1627-1653.	2.9	150

#	Article	IF	Citations
19	CALCIUMSIGNALINGMECHANISMS INT LYMPHOCYTES. Annual Review of Immunology, 2001, 19, 497-521.	9.5	760
20	Potassium channels in T lymphocytes: toxins to therapeutic immunosuppressants. Toxicon, 2001, 39, 1269-1276.	0.8	66
21	Binding of Correolide to the Kv1.3 Potassium Channel:Â Characterization of the Binding Domain by Site-Directed Mutagenesisâ€. Biochemistry, 2001, 40, 11687-11697.	1.2	54
22	Designed Peptide Analogues of the Potassium Channel Blocker ShK Toxin. Biochemistry, 2001, 40, 15528-15537.	1.2	19
23	Angular Methoxy-Substituted Furo- and Pyranoquinolinones as Blockers of the Voltage-Gated Potassium Channel Kv1.3. Journal of Medicinal Chemistry, 2001, 44, 1249-1256.	2.9	73
24	Pharmacologic Modulation of the Immune Interaction between Cytotoxic Lymphocytes and Ventricular Myocytes. Journal of Cardiovascular Pharmacology, 2001, 38, 298-316.	0.8	9
25	Effects of Toxins Pi2 and Pi3 on Human T Lymphocyte Kv1.3 Channels: The Role of Glu7 and Lys24. Journal of Membrane Biology, 2001, 179, 13-25.	1.0	35
26	WIN 17317-3 blocks Ca2+-activated K+ channels and enhances motility of guinea-pig detrusor muscle. European Journal of Pharmacology, 2001, 428, 45-49.	1.7	2
27	Selective Blocking of Voltage-Gated K+ Channels Improves Experimental Autoimmune Encephalomyelitis and Inhibits T Cell Activation. Journal of Immunology, 2001, 166, 936-944.	0.4	180
28	Isoform-specific Localization of Voltage-gated K+Channels to Distinct Lipid Raft Populations. Journal of Biological Chemistry, 2001, 276, 8409-8414.	1.6	207
29	Selective blockade of T lymphocyte K+ channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 13942-13947.	3.3	309
30	Modulation of Mouse Paneth Cell Î±-Defensin Secretion by mIKCa1, a Ca2+-activated, Intermediate Conductance Potassium Channel. Journal of Biological Chemistry, 2002, 277, 3793-3800.	1.6	90
31	Cell volume and ion changes during apoptotic cell death. Advances in Cancer Research, 2002, 85, 175-201.	1.9	5
32	Mutating a Critical Lysine in ShK Toxin Alters Its Binding Configuration in the Poreâ^'Vestibule Region of the Voltage-Gated Potassium Channel, Kv1.3. Biochemistry, 2002, 41, 11963-11971.	1.2	64
33	Identification of a New Class of Inhibitors of the Voltage-Gated Potassium Channel, Kv1.3, with Immunosuppressant Propertiesâ€. Biochemistry, 2002, 41, 7781-7794.	1.2	58
34	Invited Review: Cell Volume Control and Signal Transduction in Apoptosis. Toxicologic Pathology, 2002, 30, 541-551.	0.9	42
35	Actinomycin D-induced apoptosis involves the potassium channel Kv1.3. Biochemical and Biophysical Research Communications, 2002, 295, 526-531.	1.0	70
36	K+ channels as therapeutic drug targets. , 2002, 94, 157-182.		142

#	Article	IF	Citations
37	Incomplete Inactivation of Voltage-dependent K+ Channels in Human B Lymphoma Cells. Journal of Membrane Biology, 2002, 188, 97-105.	1.0	10
38	A potassium ion channel is involved in cytokine production by activated human macrophages. Clinical and Experimental Immunology, 2002, 130, 67-74.	1.1	34
39	Selective Blockade of Voltage-Gated Potassium Channels Reduces Inflammatory Bone Resorption in Experimental Periodontal Disease. Journal of Bone and Mineral Research, 2003, 19, 155-164.	3.1	93
40	Voltage-dependent K + channels in pancreatic beta cells: Role, regulation and potential as therapeutic targets. Diabetologia, 2003, 46, 1046-1062.	2.9	223
41	Voltage-dependent K+channel Î² subunits in muscle: Differential regulation during postnatal development and myogenesis. Journal of Cellular Physiology, 2003, 195, 187-193.	2.0	28
42	Benzamide derivatives as blockers of Kv1.3 ion channel. Bioorganic and Medicinal Chemistry Letters, 2003, 13, 1161-1164.	1.0	25
43	Molecular modeling of ion channels: structural predictions. Current Opinion in Chemical Biology, 2003, 7, 150-156.	2.8	39
44	Evidence for a function-specific mutation in the neurotoxin, parabutoxinâ€ƒ3. European Journal of Neuroscience, 2003, 17, 1786-1792.	1.2	9
45	Covalent structure and some pharmacological features of native and cleaved ?-KTx12?1, a four disulfide-bridged toxin fromTityus serrulatus venom. Journal of Peptide Science, 2003, 9, 132-140.	0.8	17
46	Di-Substituted Cyclohexyl Derivatives Bind to Two Identical Sites with Positive Cooperativity on the Voltage-Gated Potassium Channel, Kv1.3. Biochemistry, 2003, 42, 4733-4743.	1.2	19
47	The voltage-gated potassium channel subunit, Kv1.3, is expressed in epithelia. Biochimica Et Biophysica Acta - Biomembranes, 2003, 1616, 85-94.	1.4	49
48	K+ channels and T-cell synapses: the molecular background for efficient immunomodulation is shaping up. Trends in Pharmacological Sciences, 2003, 24, 385-389.	4.0	24
49	Electrophysiological Analysis of Heterologously Expressed Kv and SK/IK Potassium Channels. Current Protocols in Pharmacology, 2003, 20, Unit11.5.	4.0	3
50	Characterization of a Novel Gastropod Toxin (6-Bromo-2-mercaptotryptamine) That Inhibits Shaker K Channel Activity. Journal of Biological Chemistry, 2003, 278, 34934-34942.	1.6	32
51	Colocalization and nonrandom distribution of Kv1.3 potassium channels and CD3 molecules in the plasma membrane of human T lymphocytes. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 2592-2597.	3.3	80
52	Kv1.3 potassium channels in human alveolar macrophages. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2003, 285, L862-L868.	1.3	52
53	K+ Channel Expression during B Cell Differentiation: Implications for Immunomodulation and Autoimmunity. Journal of Immunology, 2004, 173, 776-786.	0.4	175
54	Kv1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1285-1290.	3.3	119

#	Article	IF	Citations
55	Ion channels and lymphocyte activation. Immunology Letters, 2004, 92, 55-66.	1.1	101
56	Defensin-mediated innate immunity in the small intestine. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2004, 18, 405-419.	1.0	82
57	Effect of the chlorpropamide and Fructose-1,6-bisphosphate on soluble TNF receptor II levels. Pharmacological Research, 2004, 49, 449-453.	3.1	7
58	A three-residue, continuous binding epitope peptidomimetic of ShK toxin as a Kv1.3 inhibitor. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 3193-3196.	1.0	20
59	Potent Kv1.3 inhibitors from correolideâ€"modification of the C18 position. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 447-451.	1.0	22
60	Signal Transduction by Ion Channels in Lymphocytes. , 2005, , 293-315.		0
61	Pattern of KvÎ² Subunit Expression in Macrophages Depends upon Proliferation and the Mode of Activation. Journal of Immunology, 2005, 174, 4736-4744.	0.4	54
62	International Union of Pharmacology. LIII. Nomenclature and Molecular Relationships of Voltage-Gated Potassium Channels. Pharmacological Reviews, 2005, 57, 473-508.	7.1	785
63	Using Bioinformatics for Drug Target Identification from the Genome. Molecular Diagnosis and Therapy, 2005, 5, 387-396.	3.3	35
64	Novel potent and selective calcium-release-activated calcium (CRAC) channel inhibitors. Part 2: Synthesis and inhibitory activity of aryl-3-trifluoromethylpyrazoles. Bioorganic and Medicinal Chemistry, 2006, 14, 5370-5383.	1.4	39
65	One-pot synthesis of 2-substituted furo[3,2-c]quinolines via tandem couplingâ€"cyclization under Pd/C-copper catalysis. Tetrahedron Letters, 2006, 47, 7317-7322.	0.7	43
66	Potassium channels: New targets in cancer therapy. Cancer Detection and Prevention, 2006, 30, 375-385.	2.1	114
67	Potassium channels Kv1.3 and Kv1.5 are expressed on blood-derived dendritic cells in the central nervous system. Annals of Neurology, 2006, 60, 118-127.	2.8	55
68	A Pyrazole Derivative Potently Inhibits Lymphocyte Ca2+ Influx and Cytokine Production by Facilitating Transient Receptor Potential Melastatin 4 Channel Activity. Molecular Pharmacology, 2006, 69, 1413-1420.	1.0	139
69	Characterization of the Functional Properties of the Voltage-Gated Potassium Channel Kv1.3 in Human CD4+ T Lymphocytes. Journal of Immunology, 2007, 179, 4563-4570.	0.4	86
70	Kv1.3/Kv1.5 heteromeric channels compromise pharmacological responses in macrophages. Biochemical and Biophysical Research Communications, 2007, 352, 913-918.	1.0	65
71	Nutrition and immune system: Certain fatty acids differently modify membrane composition and consequently kinetics of KV1.3 channels of human peripheral lymphocytes. Immunobiology, 2007, 212, 213-227.	0.8	13
72	Novel potent and selective Ca2+ release-activated Ca2+ (CRAC) channel inhibitors. Part 3: Synthesis and CRAC channel inhibitory activity of 4â€²-[(trifluoromethyl)pyrazol-1-yl]carboxanilides. Bioorganic and Medicinal Chemistry, 2008, 16, 9457-9466.	1.4	23

#	Article	IF	Citations
73	CRAC inhibitors: identification and potential. Expert Opinion on Drug Discovery, 2008, 3, 787-800.	2.5	27
74	K⁺ Channel Modulators for the Treatment of Neurological Disorders and Autoimmune Diseases. Chemical Reviews, 2008, 108, 1744-1773.	23.0	196
75	High-Throughput Profiling of Ion Channel Activity in Primary Human Lymphocytes. Analytical Chemistry, 2008, 80, 3728-3735.	3.2	22
76	TWIK-related Acid-sensitive K+ Channel 1 (TASK1) and TASK3 Critically Influence T Lymphocyte Effector Functions. Journal of Biological Chemistry, 2008, 283, 14559-14570.	1.6	89
77	Cannabinoids Affect Dendritic Cell (DC) Potassium Channel Function and Modulate DC T Cell Stimulatory Capacity. Journal of Immunology, 2008, 181, 3057-3066.	0.4	28
78	Voltage-Dependent Potassium Channels Kv1.3 and Kv1.5 in Human Cancer. Current Cancer Drug Targets, 2009, 9, 904-914.	0.8	71
79	Research Toward Potassium Channels on Tumor Progression. Current Topics in Medicinal Chemistry, 2009, 9, 322-329.	1.0	15
80	Role of Membrane Potential in the Regulation of Cell Proliferation and Differentiation. Stem Cell Reviews and Reports, 2009, 5, 231-246.	5.6	388
81	Comment on â€œFunctional consequences of Kv1.3 ion channel rearrangement into the immunological synapseâ€• Immunology Letters, 2009, 125, 156-157.	1.1	3
82	TRESK channel as a potential target to treat T-cell mediated immune dysfunction. Biochemical and Biophysical Research Communications, 2009, 390, 1102-1105.	1.0	22
83	Immunomodulatory effects of diclofenac in leukocytes through the targeting of Kv1.3 voltage-dependent potassium channels. Biochemical Pharmacology, 2010, 80, 858-866.	2.0	71
84	Kv1.5 in the Immune System: the Good, the Bad, or the Ugly?. Frontiers in Physiology, 2010, 1, 152.	1.3	16
85	Dendritic Cell Regulation by Cannabinoid-Based Drugs. Pharmaceuticals, 2010, 3, 2733-2750.	1.7	12
86	Immunomodulation of voltage-dependent K+ channels in macrophages: molecular and biophysical consequences. Journal of General Physiology, 2010, 135, 135-147.	0.9	74
87	Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis. American Journal of Physiology - Renal Physiology, 2010, 299, F1258-F1269.	1.3	32
88	Membrane potential of CD4+ T cells is a subset specific feature that depends on the direct cell-to-cell contacts with monocytes. Human Immunology, 2010, 71, 666-675.	1.2	7
89	Pharmacological modulation of voltage-gated potassium channels as a therapeutic strategy. Expert Opinion on Therapeutic Patents, 2010, 20, 1471-1503.	2.4	24
90	Spiro azepane-oxazolidinones as Kv1.3 potassium channel blockers: WO2010066840. Expert Opinion on Therapeutic Patents, 2010, 20, 1759-1765.	2.4	8

#	Article	IF	Citations
91	Immune cells recruitment and activation by Tityus serrulatus scorpion venom. Toxicon, 2011, 58, 480-485.	0.8	38
92	Volume regulation of murine T lymphocytes relies on voltage-dependent and two-pore domain potassium channels. Biochimica Et Biophysica Acta - Biomembranes, 2011, 1808, 2036-2044.	1.4	39
93	The Therapeutic Potential of Adenosine Triphosphate as an Immune Modulator in the Treatment of HIV/AIDS: A Combination Approach with HAART. Current HIV Research, 2011, 9, 209-222.	0.2	10
94	Whole-Cell Electrical Activity Under Direct Mechanical Stimulus by AFM Cantilever Using Planar Patch Clamp Chip Approach. Cellular and Molecular Bioengineering, 2011, 4, 270-280.	1.0	11
95	Synthesis of C3-nitroalkylated-4-hydroxycoumarin and hydroxyiminodihydrofuroquinolinone derivatives via the Michael addition of cyclic 1,3-dicarbonyl compounds to Î²-nitrostyrenes. Tetrahedron, 2011, 67, 2870-2877.	1.0	26
96	Targeting the Voltage-Dependent K+ Channels Kv1.3 and Kv1.5 as Tumor Biomarkers for Cancer Detection and Prevention. Current Medicinal Chemistry, 2012, 19, 661-674.	1.2	62
97	KCNE2 and the K⁺channel. Channels, 2012, 6, 1-10.	1.5	35
98	Molecular cloning and functional analysis of a voltage-gated potassium channel in lymphocytes from sea perch, Lateolabrax japonicus. Fish and Shellfish Immunology, 2012, 33, 605-613.	1.6	3
99	A facile eco-friendly three-component protocol for the regio- and stereoselective synthesis of functionalized trans-dihydrofuro[3,2-c]-quinolin-4(2H)-ones. Green Chemistry, 2012, 14, 3361.	4.6	39
100	Conotoxins that Confer Therapeutic Possibilities. Marine Drugs, 2012, 10, 1244-1265.	2.2	86
101	The Antibody Targeting the E314 Peptide of Human Kv1.3 Pore Region Serves as a Novel, Potent and Specific Channel Blocker. PLoS ONE, 2012, 7, e36379.	1.1	18
102	Kv1.3 blockers ameliorate allergic contact dermatitis by preferentially suppressing effector memory T cells in a rat model. Clinical and Experimental Dermatology, 2013, 38, 897-903.	0.6	10
103	Identification of two-pore domain potassium channels as potent modulators of osmotic volume regulation in human T lymphocytes. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 699-707.	1.4	23
104	Modulation of Voltage-Dependent and Inward Rectifier Potassium Channels by 15-Epi-Lipoxin-A4 in Activated Murine Macrophages: Implications in Innate Immunity. Journal of Immunology, 2013, 191, 6136-6146.	0.4	35
105	The voltage-dependent K+ channels Kv1.3 and Kv1.5 in human cancer. Frontiers in Physiology, 2013, 4, 283.	1.3	99
106	Scorpion Venom Interactions with the Immune System. , 2013, , 1-18.		3
107	NMDA-receptor antagonists block B-cell function but foster IL-10 production in BCR/CD40-activated B cells. Cell Communication and Signaling, 2014, 12, 75.	2.7	40
108	Essential Functional Modules for Pathogenic and Defensive Mechanisms inCandida albicansInfections. BioMed Research International, 2014, 2014, 1-15.	0.9	7

#	Article	IF	Citations
109	Kcnn4 Is a Regulator of Macrophage Multinucleation in Bone Homeostasis and Inflammatory Disease. Cell Reports, 2014, 8, 1210-1224.	2.9	53
110	The complex cascade of cellular events governing inflammasome activation and IL-1Î² processing in response to inhaled particles. Particle and Fibre Toxicology, 2015, 13, 40.	2.8	68
112	Novel therapies for memory cells in autoimmune diseases. Clinical and Experimental Immunology, 2015, 180, 353-360.	1.1	22
113	Involvement of potassium channels in the progression of cancer to a more malignant phenotype. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 2477-2492.	1.4	106
114	Scorpion Venom Interactions with the Immune System. , 2015, , 87-107.		6
115	Cortisone and hydrocortisone inhibit human Kv1.3 activity in a non-genomic manner. Naunyn-Schmiedeberg's Archives of Pharmacology, 2015, 388, 653-661.	1.4	2
116	Classical Targets in Drug Discovery. , 2015, , 87-142.		0
117	Increase in the titer of lentiviral vectors expressing potassium channels by current blockade during viral vector production. BMC Neuroscience, 2015, 16, 30.	0.8	9
118	â€œDisease modifying nutricalsâ€•for multiple sclerosis. , 2015, 148, 85-113.		42
119	Using the SMOTE technique and hybrid features to predict the types of ion channel-targeted conotoxins. Journal of Theoretical Biology, 2016, 403, 75-84.	0.8	15
120	Molecular characterization and functional analysis of four teleostean K + channels in macrophages of sea perch (Lateolabrax japonicas). Fish and Shellfish Immunology, 2017, 60, 426-435.	1.6	0
121	p-TSA-catalyzed facile and efficient one-pot eco-friendly synthesis of novel isoxazolyl amino furo[3,2-c]quinolinone derivatives in aqueous medium. Tetrahedron Letters, 2017, 58, 3859-3863.	0.7	9
122	Venoms. , 2017, , 99-128.		3
123	Intracellular fluoride influences TASK mediated currents in human T cells. Journal of Immunological Methods, 2020, 487, 112875.	0.6	2
124	Non-dioxin-like polychlorinated biphenyl 19 has distinct effects on human Kv1.3 and Kv1.5 channels. Toxicology and Applied Pharmacology, 2021, 411, 115365.	1.3	0
126	Classical targets in drug discovery. , 2021, , 111-183.		0
127	KCNE4-dependent functional consequences of Kv1.3-related leukocyte physiology. Scientific Reports, 2021, 11, 14632.	1.6	4
128	Potassium channels: Gene family, therapeutic relevance, high-throughput screening technologies and drug discovery. , 2002, 58, 133-168.		23

#	Article	IF	Citations
129	Calcineurin-independent inhibition of KV1.3 by FK-506 (tacrolimus): a novel pharmacological property. American Journal of Physiology - Cell Physiology, 2007, 292, C1714-C1722.	2.1	13
130	Effects of 3,3â€™,4,4â€™,5-pentachlorobiphenyl on human Kv1.3 and Kv1.5 channels. International Journal of Oral Biology: Official Journal of the Korean Academy of Oral Biology and the UCLA Dental Research Institute, 2019, 44, 115-123.	0.1	1
132	Potassium channels in C. elegans. WormBook, 2006, , 1-15.	5.3	44
133	Ion Channels as Therapeutic Targets for Type 1 Diabetes Mellitus. Current Drug Targets, 2020, 21, 132-147.	1.0	7
134	Modulation of Adaptive Immunity and Viral Infections by Ion Channels. Frontiers in Physiology, 2021, 12, 736681.	1.3	8
135	Inhibitory effect of the selective serotonin reuptake inhibitor paroxetine on human Kv1.3 channels. European Journal of Pharmacology, 2021, 912, 174567.	1.7	4
136	Antimicrobial Peptide Effectors of Small Intestinal Innate Immunity. , 0, , 191-221.		0
137	Extracellular flux analyses reveal differences in mitochondrial PBMC metabolism between high-fit and low-fit females. American Journal of Physiology - Endocrinology and Metabolism, 2022, 322, E141-E153.	1.8	8
138	Smouldering fire or conflagration? An illustrated update on the concept of inflammation in pulmonary arterial hypertension. European Respiratory Review, 2021, 30, 210161.	3.0	5
139	Diterpenoids with Rearranged 9(10â†'11)-abeo-10,12-Cyclojatrophane Skeleton and the First (15S)-Jatrophane from Euphorbia helioscopia: Structural Elucidation, Biomimetic Conversion, and Their Immunosuppressive Effects. Organic Letters, 2022, 24, 697-701.	2.4	14
140	Repetitive transcranial magnetic stimulation enhances the neuronal excitability of mice by regulating dynamic characteristics of Granule cellsâ€™ Ion channels. Cognitive Neurodynamics, 0, , .	2.3	0
141	Retroviral glycoprotein-mediated immune suppression via the potassium channel KCa3.1 â€“ A new strategy for amelioration of inflammatory bowel diseases. Clinical Immunology, 2022, 242, 109081.	1.4	1
142	Potassium channel-related genes are a novel prognostic signature for the tumor microenvironment of renal clear cell carcinoma. Frontiers in Oncology, 0, 12, .	1.3	1
143	The protective role of interaction between vitamin D, sex hormones andÂcalcium in multiple sclerosis. International Journal of Neuroscience, 0, , 1-19.	0.8	2
144	HIV-1 Nef Expression Inhibits the Activity of a Ca2+-Dependent K+ Channel Involved in the Control of the Resting Potential in CEM Lymphocytes. Journal of Immunology, 1999, 162, 5359-5366.	0.4	25